| [1] |
YU Jing, PALATI Reheman, ZHAO Ting, FENG Jirong, SUN Yan, HE Lei.
Correlation of the efficacy, safety and plasma concentration of lacosamide in the treatment of children with epilepsy under 4 years of age
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 559-562.
|
| [2] |
LI Ning, JIANG Xiaoya, ZHANG Zezhao, GAO Le, WANG Xinguo, LIU Xiaoming.
Preparation and quality evaluation of standard decoctions of Rosa chinensis Jacq.
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 397-402.
|
| [3] |
CHEN Tianyu, CHEN Qiying, ZHANG Yuezhen.
Adverse reactions of solriamfetol after listing based on real world data
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 432-435.
|
| [4] |
NIE Xiaolu, PENG Yaguang, SUN Zimo, PENG Xiaoxia.
Threshold setting of biochemical indexes related to diagnosis of drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 244-247.
|
| [5] |
WU Hao, ZHANG Bing, LIN Zhijian, ZHANG Xiaomeng.
Comparison of International Pharmacovigilance of Traditional Chinese Medicine and Natural Medicines
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 406-410.
|
| [6] |
ZHANG Dan, LYU Jintao, ZHANG Bing, LIN Zhijian, WU Huanzhang, ZHANG Xiaomeng.
Construction and Application of Four-Dimensional and Chained Research Platform for Pharmacovigilance of Traditional Chinese Medicine
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 416-421.
|
| [7] |
SA Rina, ZHANG Bing, LIN Zhijian, WANG Xiaofang, ZHANG Xiaomeng.
Pharmacovigilance of Traditional Chinese Medicine in Pharmaceutical Care in Medical Institutions
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 422-426.
|
| [8] |
HAN Qiwen, WEN Lu, CHEN Naihong, YUAN Yuhe.
Changes of α-Synuclein in A53T Transgenic Mice
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(4): 312-314.
|
| [9] |
ZHOU Xiangzhen, LI Jingtai, REN Shaolin, ZHANG Chunping, ZHANG Tianhua.
One Case of Severe Skin Damage Induced by Combination of Doxorubicin Hydrochloride Liposome Injection and Paclitaxel for Injection (albumin-binding)
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(3): 280-283.
|
| [10] |
ZHANG Yongna, ZHANG Yanjiao, ZHAO Li, HAN Yongxin.
One Case of Drug Treatment and Pharmaceutical Care in Patients with HIT after Coronary Artery Bypass Grafting
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(3): 284-288.
|
| [11] |
CAI Jun, LI Huixin, LIU Mengying, YAO Yao, GE Weihong.
Safe Use of Lopinavir/Ritonavir for COVID-19 Based on Literature Analysis of Adverse Reactions
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(6): 326-331.
|
| [12] |
BIE Zhi-xin, DING Li.
Clinical Characteristics of Patients with Interstitial Lung Disease Induced by Gefitinib and Erlotinib
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(5): 309-312.
|
| [13] |
.
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(1): 55-56.
|
| [14] |
YU Da-Hai, CHENG Mei, LI Bei.
Analysis of 32 Cases of Adverse Drug Reaction Caused by Cervus and Cucumis Polypeptide Injection
[J]. Chinese Journal of Pharmacovigilance, 2011, 8(6): 373-375.
|
| [15] |
SONG Jun, ZHAO Jun-ning ,WU Cheng-yun ,ZHOU Ya-li.
Non-Clinical Safety Study's Role on Safety Reassessment of Post-Marketing Traditional Chinese Medicine
[J]. Chinese Journal of Pharmacovigilance, 2010, 7(12): 730-732.
|
